跳至主要内容
临床试验/NCT00727220
NCT00727220已完成不适用

A Prospective Study of the Impact of CSII Therapy in Young Children With Type 1 DM

Indiana University1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 1999年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
42
试验地点
1
主要终点
Change in HgBA1c

研究概览

简要总结

The purpose of the study is to examine glycemic and neuropsychological outcomes in very young children with Type I diabetes who are being started on insulin pumps and to compare their outcomes to children who are not utilizing insulin pumps. We propose to assess 40 children with IDDM under 5 years of age. 10 patients examined will be using multiple daily injections with basal glargine, 10 will be using NPH or Lente and rapid-acting insulin, and 20 will be examined prior to and 12 months after the implementation of insulin pump therapy. These subjects will be recruited and followed because they are currently undergoing treatment for Type 1 diabetes. Children will be recruited based upon the insulin regimen that they and their primary diabetes physician have chosen to utilize clinically. Insulin regimens will not be changed by the study team. Outcome measures will examine: glycemic outcomes (overall control, blood sugar variability), cognitive outcomes, parenting Stress, and changes in diet.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Year 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children with Type I diabetes:
  • Children must be 5 years of age or less at the time of entry into the study.
  • Children must have had a diagnosis of type I diabetes for at least 1 year at time of entry.
  • Children must be receiving two or more insulin injections daily.

排除标准

  • Children will be excluded if they have additional medical problems requiring treatment with agents known to affect blood glucose such as steroids or L-asparaginase.
  • Children must not have any other chronic illness in addition to diabetes.

结局指标

主要结局

Change in HgBA1c

时间窗: Baseline and 6 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Linda DiMeglio, MD

MD

Indiana University

研究点 (1)

Loading locations...

相似试验

Unknown
不适用
The Impact of Milk-products Differing in Their Glycaemic Properties on the Behaviour of InfantsMood BehaviourCognitive Function
NCT01589003Geok Lin Khor70
进行中(未招募)
2 期
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Recurrent EpendymomaRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant GliomaRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Rhabdoid TumorRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRecurrent WHO Grade 2 GliomaRefractory EpendymomaRefractory Ewing SarcomaRefractory HepatoblastomaRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant GliomaRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaRefractory WHO Grade 2 GliomaWilms Tumor
NCT04195555National Cancer Institute (NCI)3
进行中(未招募)
2 期
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaHistiocytic SarcomaJuvenile XanthogranulomaLangerhans Cell HistiocytosisMalignant GliomaRecurrent Childhood RhabdomyosarcomaRecurrent EpendymomaRecurrent Ewing SarcomaRecurrent GliomaRecurrent HepatoblastomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Primary Central Nervous System NeoplasmRecurrent Rhabdoid TumorRecurrent Soft Tissue SarcomaRefractory Ewing SarcomaRefractory GliomaRefractory HepatoblastomaRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Primary Central Nervous System NeoplasmRefractory Rhabdoid TumorRefractory RhabdomyosarcomaRhabdoid TumorStage III Osteosarcoma AJCC v7Stage III Soft Tissue Sarcoma AJCC v7Stage IV Osteosarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Stage IVA Osteosarcoma AJCC v7Stage IVB Osteosarcoma AJCC v7Wilms Tumor
NCT03155620National Cancer Institute (NCI)1,377
已完成
2 期
Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic HypoglycemiaCongenital Hyperinsulinism (CHI)Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
NCT01468454Children's Hospital of Philadelphia130
Unknown
不适用
Investigating Best Practices for Children With Cerebral Palsy: A Pilot Study of Two ApproachesCerebral Palsy
NCT00430131University of Toronto18